CompoAtlas

Allicidin

En vente sur le marché américain (selon le DSLD)

Premier Research Labs, food supplement from the US market

Allicidin (Premier Research Labs), a food supplement au code-barres 807735025915, is described by its US market label. If sold in France, it would be subject to 1 point of French or European regulation, detailed below. The formula sold in Europe under the same name may differ.

Official label. Dietary Supplement Label Database (DSLD), US National Institutes of Health: current and off-market labels, retrieved 27 October 2026.

Source: NIH Office of Dietary Supplements, Dietary Supplement Label Database (CC0); US market labels.

Displayed label: Official label. Labels on the market are prioritised, followed by the most recent for the same status.

If this product were sold in France

A daily dose is calculated only if the label gives the maximum number of servings and a unit of mass (or international units for vitamin D). Quantities come from the label, not an analysis. In the United States, the label presents this product as a ‘dietary supplement’; in France, a product of this type may belong to another category (a sports powder, for example), and maximum food supplement doses do not apply to it.

Label composition

Brand
Premier Research Labs
Barcode
807735025915
Form
Capsule
One serving
2 capsules
Servings
up to 1 serving per day
Other ingredients (in English, as written)
Plant-Source Capsules
Ingredient (as written, in English)CategoryPer serving
Allicin OrganoSulfur ComplexBlend630 mg
Garlic (bulb) extract (Allium sativum)Plantnot stated
Wild Bear Garlic (Allium sativum)Plantnot stated
S-Allyl CysteineOther substance190 µg
AllicinOther substance3,780 µg
AlliinOther substance6 mg
organic Turkey TailsOther72 mg
Hyssop (Hyssopus officinalis)Plant72 mg
organic Parsley (Petroselinum crispum)Plant72 mg

Other versions of this label

The differences below describe each other version relative to the label shown on this page. They concern active ingredient rows and quantities per serving as written. Missing quantities are not estimated and different units are not converted. Dates refer to entry into DSLD, not necessarily to a formula change.

This information reproduces the US label recorded by the US National Institutes of Health (NIH). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Garlic (bulb) extract
    Read the warning, when it applies and the studies cited

    Garlic - Allium sativum

    Route of administration: Oral

    Cautions and warnings

    Condition of application: Relief of upper respiratory tract infections and catarrhal (nasal congestion) conditions.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Condition of application: All uses.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners or protease inhibitors (Brinker 2010; Mills and Bone 2005).

    2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant (Brinker 2010; Mills and Bone 2005).

    2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have diabetes (Brinker 2010; Mills and Bone 2005).

    2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Known adverse reactions

    Stop use if hypersensitivity/allergy occurs (Brinker 2010; Mills and Bone 2005).

    2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Health Canada monograph dated 30 January 2026

  • Hyssop
    Read the warning, when it applies and the studies cited

    Hyssop - Hyssop Officinalis

    Route of administration: Oral

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are breastfeeding.

    Contraindications

    Do not use if you are pregnant (Gardner and McGuffin 2013; Bradley 2006).

    2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Health Canada monograph dated 30 January 2026

They concern the ingredient, not this product or its dose. They do not replace medical advice.

List declared on (register: Dietary Supplement Label Database (DSLD), US National Institutes of Health: current and off-market labels).

Photograph the packaging

Brand : Premier Research Labs

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

List recorded in 2022. Photograph the packaging to check whether it has changed.

Enter to analyse, Shift+Enter for a new line